Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Current Investments: 2021-2025

Historic Cash & Current Investments for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $288.2 million.

  • ARS Pharmaceuticals' Cash & Current Investments rose 40.85% to $288.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 27.73%. This contributed to the annual value of $314.0 million for FY2024, which is 37.51% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Cash & Current Investments of $288.2 million as of Q3 2025, which was up 20.02% from $240.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Cash & Current Investments' 5-year high stood at $374.2 million during Q1 2021, with a 5-year trough of $60.1 million in Q4 2021.
  • In the last 3 years, ARS Pharmaceuticals' Cash & Current Investments had a median value of $241.9 million in 2023 and averaged $250.2 million.
  • Data for ARS Pharmaceuticals' Cash & Current Investments shows a peak YoY increase of 356.82% (in 2022) and a maximum YoY decrease of 32.16% (in 2022) over the last 5 years.
  • ARS Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $60.1 million in 2021, then soared by 356.82% to $274.4 million in 2022, then dropped by 16.77% to $228.4 million in 2023, then soared by 37.51% to $314.0 million in 2024, then surged by 40.85% to $288.2 million in 2025.
  • Its Cash & Current Investments stands at $288.2 million for Q3 2025, versus $240.1 million for Q2 2025 and $275.7 million for Q1 2025.